Quick Takeaways
- BAILLIE GIFFORD & CO filed SCHEDULE 13G/A for RECURSION PHARMACEUTICALS, INC. Class A Common Stock (RXRX).
- Disclosed ownership: 4.6%.
- Date of event: 31 Dec 2025.
BAILLIE GIFFORD & CO - 31 Dec 2025 SCHEDULE 13G/A Report for RECURSION PHARMACEUTICALS, INC. Class A Common Stock (RXRX)
- Filing Manager
- BAILLIE GIFFORD & CO
- Reporting Manager
- BAILLIE GIFFORD & CO
- Symbol
- RXRX
- Shares outstanding
- 516,847,217 shares
- Disclosed Ownership
- 23,774,972 shares
- Ownership
- 4.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 05 Feb 2026, 10:04:18 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BAILLIE GIFFORD & CO disclosed 4.6% ownership in RECURSION PHARMACEUTICALS, INC. Class A Common Stock (RXRX) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 05 Feb 2026, 10:04.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO | 4.6% | 23,774,972 | 23,730,293 | 0 | Grant Meikle | Regulatory Reporting Manager |